The contamination of valsartan and other sartans, part 1: New findings-Reference-Cited by-同舟云学术

The contamination of valsartan and other sartans, part 1: New findings

Published:2019-08 Issue: Volume:172 Page:395-405
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Sörgel Fritz,Kinzig Martina,Abdel-Tawab Mona,Bidmon Clemens,Schreiber André,Ermel Steffen,Wohlfart Jonas,Besa Axel,Scherf-Clavel Oliver,Holzgrabe Ulrike

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference27 articles.

1. Agents affecting the renin-angiotensin pathway and calcium blockers;Herold,2013

2. Discovery and Development of Angiotensin Receptor Blockers,2019

3. Statistics by Health Insurance Companies of Medicines Used in Germany,2019

4. Valsartan: chargenbezogener Rückruf valsartanhaltiger Arzneimittel, deren Wirkstoff von dem chinesischen Hersteller Zhejiang Huahai Pharmaceutical produziert wurde Pressemitteilung 5/18,2019

5. First report of EMA about contamination of valsartan tablets from Zhejiang Huahai,2019

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nitrosamine contamination of pharmaceuticals: Cases in Japan, formation mechanisms, detection methods, regulatory perspectives, and insights;Journal of Pharmaceutical and Biomedical Analysis Open;2024-12

2. Targeted and untargeted screening for impurities in losartan tablets marketed in Germany by means of liquid chromatography/high resolution mass spectrometry;Journal of Pharmaceutical and Biomedical Analysis;2024-08

3. Nitrite in Pharmaceutical Manufacturing Water: Development of an Ultra-Sensitive Analytical Method, Typical Data, and Discussion of Potential Nitrosamine Formation in Drug Substance and Drug Product from Water;Organic Process Research & Development;2024-06-12

4. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA);Regulatory Toxicology and Pharmacology;2024-06

5. A Headspace Gc-Ms Method to Quantify Nitrosamine Impurities and Precursors in Drug Products: Method Validation and Product Testing;2024